Tocilizumab Treatment for Nephrotic Syndrome Due to Amyloidosis in Behcet’s Disease
| Autor: | E Andrada, R Enríquez, R. Noguera-Pons, Isabel Millán, A E Sirvent, F Amorós, M D Redondo-Pachón |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
medicine.medical_specialty
Nephrotic Syndrome Disease Behcet's disease Antibodies Monoclonal Humanized Kidney Critical Care and Intensive Care Medicine Gastroenterology chemistry.chemical_compound Tocilizumab AA amyloidosis Internal medicine medicine Humans business.industry Behcet Syndrome Amyloidosis General Medicine Middle Aged medicine.disease Treatment Outcome chemistry Nephrology Immunology Etiology Female business Complication Nephrotic syndrome |
| Zdroj: | Renal Failure. 35:547-550 |
| ISSN: | 1525-6049 0886-022X |
| DOI: | 10.3109/0886022x.2013.773913 |
| Popis: | Renal involvement is an unusual but significant Behcet´s disease (BD) complication and AA amyloidosis appears to be the most common etiology. IL-6 is a pro-inflammatory cytokine with an important role in AA amyloidosis development. Tocilizumab (TCZ) is a humanized anti-IL-6 receptor antibody that has emerged as an effective and specific treatment in AA amyloidosis secondary to chronic inflammatory disorders. We report on a patient diagnosed with BD who developed nephrotic syndrome caused by renal AA amyloidosis with an excellent response to TCZ therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |